Video & Transcript : 'pharmaceutical compounding' :
Page 16 of 172
NH
New Hampshire 2026 Regular Session
House Health, Human Services and Elderly Affairs (02/04/2026)
Health, Human Services and Elderly Affairs
Transcript Highlights:
- </c><00:08:40.479><c> industry</c> mandated and the pharmaceutical industry mandated and the pharmaceutical
- </c><01:00:26.880><c> cartel</c> is that our pharmaceutical cartel is that our pharmaceutical cartel
- </c><01:13:01.280><c> industry</c> profits for the pharmaceutical industry profits for the pharmaceutical
- Does your organization take financial support from pharmaceutical companies?
- </c> pharmaceutical companies? pharmaceutical companies?
US
US Federal 2025-2026 Regular Session
Hearings to examine the nomination of Robert F. Kennedy, Jr., of California, to be Secretary of Health and Human Services. Jan 30th, 2025 at 09:00 am
Health, Education, Labor, and Pensions Committee
Transcript Highlights:
- But also, more importantly, through the Commerce Department and meeting directly with pharmaceutical
- We have 4.2% of the world's population and we take 50% of the pharmaceutical drugs.
- We're the only country that allows full-scale pharmaceutical ads on TV.
- Let's not just do something for the pharmaceutical company. So I appreciate you doing that.
- They did not come from the executives—not one nickel of PAC money from the pharmaceutical industry.
NH
New Hampshire 2025 Regular Session
House Criminal Justice and Public Safety (01/23/2025)
Criminal Justice and Public Safety
Transcript Highlights:
- pharmacies do not have the compounding pharmacies do not have the oversight<05:00:34.878><c> that</c
- They would have difficulty surviving without a number of pharmaceutical medications that are required
- They would have difficulty surviving without a number of pharmaceutical medications that are required
- They would have difficulty surviving without a number of pharmaceutical medications that are required
- They would have difficulty surviving without a number of pharmaceutical medications that are required
NH
New Hampshire 2026 Regular Session
House Environment and Agriculture (02/17/2026)
Environment and Agriculture
Transcript Highlights:
- I move on to HB 1192, exempting certain household pharmaceutical waste from the definition of hazardous
- We know there are thousands, 15,000 and counting different PFAS compounds, but this particular method
- It depends on the PFAS compound.
Summary:
The subcommittee held an open work session on HB 1766-FN, a bill addressing cruelty to livestock, and focused on proposed language changes from the Department of Agriculture. Assistant State Veterinarian Nathan Harvey, speaking for the commissioner, explained concerns about the term “imminent danger,” arguing that the bill should allow seizure based on probable cause when an animal is starving or has a life-threatening condition, rather than tying action too closely to whether the owner is arrested. The department also proposed language on “extreme suffering” that would require euthanasia if the cost of treatment would exceed the allowable reimbursement amount under AGR rules, though members immediately raised concerns about using a dollar limit to require euthanasia. The department further suggested clarifying who may participate in investigations by allowing the state veterinarian or a designate, and noted that the current draft could be read too narrowly.
Members discussed the $5,000 emergency care cap in the rules, with Josh Marshall confirming it is an aggregate emergency veterinary care limit. Several legislators said they were uncomfortable changing the bill from “may” to “shall” euthanize, arguing that treatment costs vary widely by species and condition and that a fixed monetary threshold could be too rigid. Representative Bixby also raised a separate concern that the bill’s language may be broader than intended and could apply to all animals rather than livestock only. The department agreed the bill should be limited to livestock and suggested using existing statutory definitions or adding a new section to make that clear.
The discussion also turned to humane societies and other organizations that might investigate complaints or board seized animals. A representative from a humane organization said the groups with expertise in care often also have expertise useful to investigations, and that removing them entirely could be impractical because only a few facilities in the state can provide boarding. Members and witnesses explored alternative language that would allow for-profit and nonprofit organizations to participate in either the investigation or the care of livestock, but not both, to avoid conflicts of interest while preserving needed expertise. No votes were taken; the work session ended with agreement to consult the Office of Legislative Services and the department to refine the bill before the next meeting.
KY
Kentucky 2025 Regular Session
House Standing Committee on Banking & Insurance (3-12-25)
Transcript Highlights:
- It is the pharmaceutical companies that are the ones setting the high prices of drugs, and we're here
- </c> negotiate with the pharmaceutical negotiate with the pharmaceutical companies<00:31:01.039><c> to
- </c><00:33:15.240><c> companies</c> drugs it's the pharmaceutical companies drugs it's the pharmaceutical
- </c><00:36:02.119><c> prices</c> impact pharmaceutical prices impact pharmaceutical prices specifically
- </c><00:36:21.599><c> advertising</c> to me is the pharmaceutical advertising to me is the pharmaceutical
Keywords:
Meeting Start: 00:00
Roll Call: 00:10
SB145 Discussion: 02:23
SB145 Vote: 05:13
SB183 Discussion: 06:13
SB183 Vote: 11:37
HB413 Discussion Only: 16:15, 958, all
Summary:
The House Standing Committee on Banking and Insurance met with a quorum and first took up Senate Bill 145, sponsored by Sen. David Givens. The bill would update retail installment contract statutes for automobile sales, allowing retailers with installment contracts shorter than 28 days to begin collections after three days instead of waiting for multiple missed payments, and it also harmonizes a related dollar amount in statute from $10 to $15. The committee asked no questions, and the bill received a favorable expression on a roll-call vote.
The committee then heard Senate Bill 183 from Sen. Matt Nunn, with testimony from Chris Nolan of the American Property Casualty Insurance Association. The bill would require proxy advisers acting for the State Retirement System to act solely in the financial interest of current and future retirees and to avoid political or social considerations in shareholder voting recommendations. Supporters argued it would keep politics out of public pensions and align proxy advice with fiduciary duties; members praised the bill and noted Kentucky could be among the first states to adopt such a model. The committee approved the bill with favorable expression after a roll-call vote.
The committee also reviewed administrative regulation 808 KAR 9:10 from the Department of Financial Institutions, with no vote required. It then took up House Bill 413, a PBM rebate pass-through bill, with testimony from Sarah Wood of the Diabetes Patient Advocacy Coalition. She said the bill would require 85% of negotiated drug rebates to be passed through to patients at the point of sale, lowering out-of-pocket costs, especially for high-rebate drugs such as insulin, while still allowing 15% to remain with plans. She cited examples from other states and argued the bill would benefit about 650,000 Kentuckians. Hope McClaflin of Anthem opposed the bill, saying it would reduce employers’ ability to use rebates to lower premiums, could disproportionately favor high-cost brand-name drug users, and could create significant costs for state and fully insured plans. Members asked questions about other states’ pass-through rates and the effect on premiums, but no final action on House Bill 413 was taken in the portion of the meeting provided.
MO
Missouri 2026 Regular Session
Veterans and Armed Forces Feb 3rd, 2026 at 12:00 pm
Veterans and Armed Forces
Transcript Highlights:
- But if it's being treated with pharmaceuticals, that costs money too.
- It costs money to provide pharmaceuticals for the chainsaw method.
- But if it's being treated with pharmaceuticals, that costs money too.
- It costs money to provide pharmaceuticals for the chainsaw method.
- It costs money to provide pharmaceuticals for the chainsaw method.
ID
Idaho 2026 Regular Session
Agenda Feb 26th, 2026
Transcript Highlights:
- In this, The help comes from a pharmaceutical company, who has an interest in helping because they want
- Is this going to be killing generic competition in the state with regard to these pharmaceuticals?
- Is this going to be killing generic competition in the state with regard to these pharmaceuticals?
- Is this going to be killing generic competition in the state with regard to these pharmaceuticals?
- I'm not able, as I stand here today, ...to isolate down to just the pharmaceutical benefit.
Summary:
The committee first introduced RS 33403, a follow-on podiatry bill that would merge podiatry with the Board of Medicine and move certain rules into statute. Representative Ehlers explained it was a replacement for prior legislation, and the committee voted to introduce it without objection.
The committee then heard House Bill 713 on copay accumulator policies. Representative Cannon and co-sponsor Representative Furman argued the bill would stop insurers from refusing to count third-party copay assistance toward deductibles and out-of-pocket maximums, especially for patients with expensive specialty drugs. Supporters, including patients and advocates, described serious financial hardship and treatment adherence problems caused by accumulators. Opponents, including the Idaho Association of Health Plans, argued the bill would raise costs and premiums, could conflict with Idaho’s anti-kickback law, and might interfere with private plan design. After debate, the committee voted 7-8 against the motion to send HB 713 to the floor, so the bill was held in committee.
Next, the committee took up House Bill 655 and its related RS 33527, a pilot program to incentivize preceptorships by giving certain Medicaid providers a 12-month exemption from prior authorization requirements. The sponsor said the goal was to reduce administrative burden and increase training opportunities in rural areas and in family practice, psychiatry, and OB-GYN, with caps on participation and expansion to advanced practice providers and PAs in the RS. The committee first voted to hold HB 655 in committee, then approved RS 33527 for introduction and second reading.
Finally, the committee heard House Bill 723 on children’s residential facilities. Representative Erickson said the bill would add quality-of-care oversight, annual unannounced inspections, resident and staff interviews, a youth bill of rights, and critical incident reporting, based on an OPE study and prior testimony about abuse and gaps in oversight. Testifiers, including parents and former residents, described abuse, isolation, and lack of reporting mechanisms in facilities and supported the bill. The committee discussed whether the bill created enforceable rights, but the sponsor said existing child protection and corrective action processes would apply. The bill was moved to the floor with a due pass recommendation.
TX
Transcript Highlights:
- This is a voluntary program for pharmaceutical manufacturers.
- Those restrictions come from the pharmaceutical manufacturers themselves. All right.
- The pharmaceuticals are strangling delivery.
- Pharmaceuticals making a heck of a lot of money. But my rural hospitals are not.
- There are over 20,000 pharmaceutical manufacturers.
MN
Minnesota 2025-2026 Regular Session
Committee on Judiciary and Public Safety - Part 2 - 03/27/26
Judiciary and Public Safety
Transcript Highlights:
- 24:02.160><c> is</c> Of those trillions, pharmaceutical is Of those trillions, pharmaceutical is the<
- <01:24:13.080><c> companies</c> pharmaceutical companies pharmaceutical companies spend<01:24:15.600>
- </c> millions of dollars on pharmaceuticals. millions of dollars on pharmaceuticals.
- </c> many pharmaceutical commercials either. many pharmaceutical commercials either.
- </c> profit margin of the pharmaceutical profit margin of the pharmaceutical company?
ID
Transcript Highlights:
- In this example, the help comes from a pharmaceutical company who has an interest in helping because
- Now there are a lot of charities out there, pharmaceutical companies, who are ready and willing to help
- In this legislation, is it specifically for pharmaceuticals, or does it include everything like primary
- So the pharmaceutical companies and pharmacies aren't necessarily getting—nothing changes for them for
- Is this going to be killing generic competition in the state with regard to these pharmaceuticals?
Summary:
The committee first introduced RS 33403, a follow-on to prior podiatry legislation that would merge podiatry medical practice oversight with the Board of Medicine and move certain rules into statute. The motion to introduce passed without objection. The committee then heard House Bill 713, which would ban copay accumulator policies so third-party copay assistance counts toward a patient’s deductible and out-of-pocket maximum. The sponsors and supporters argued the bill helps patients with expensive chronic conditions, while opponents from Idaho health plans and some members raised concerns about higher premiums, market interference, and possible conflict with Idaho’s anti-kickback law. After testimony from patients and advocates, the committee rejected the bill on a roll call vote, 7 ayes and 8 nays, and held it in committee.
The committee next took up House Bill 655 and RS 33527, a pilot program aimed at reducing prior authorization burdens for certain Medicaid providers who precept medical students, with the goal of encouraging more rural training and future practice in Idaho. The bill would apply only to Medicaid, cap participation, and include family practice, psychiatry, OB-GYN, and later advanced practice providers and physician assistants. After discussion about the pilot structure and administrative burden, the committee voted to hold HB 655 in committee but then approved RS 33527 for introduction and sent it to the second reading calendar.
Finally, the committee heard House Bill 723 on children’s residential facilities. The bill adds quality-of-care oversight, annual unannounced inspections, resident and staff interviews, a youth bill of rights, and critical incident reporting requirements, all intended to address problems identified in an OPE report and testimony about abuse and lack of oversight in facilities. Supporters described serious harm to children and the need for clearer rights and reporting mechanisms; the sponsor said the bill uses existing systems to avoid new costs. The committee passed HB 723 to the floor with a due pass recommendation.
MN
Minnesota 2025-2026 Regular Session
House Republican Media Availability 5/17/26
Minnesota House Floor Meeting
Transcript Highlights:
- you discuss why 340B was not included in the help omnibus and what your discussions with the pharmaceutical
- Uh, the discussions weren't with the pharmaceutical companies.
- </c> have had with the pharmaceutical have had with the pharmaceutical industry.<00:19:55.000><c> Can
- </c> discussions with the pharmaceutical discussions with the pharmaceutical industry<00:20:02.480><c
- </c><00:20:05.960><c> The</c> pharmaceutical companies. The pharmaceutical companies.
CA
California 2025-2026 Regular Session
Senate Budget and Fiscal Review Subcommittee No. 3 on Health and Human Services Mar 19th, 2026
Transcript Highlights:
- It is a compounding cascade of losses hitting community health centers simultaneously, and nowhere will
- The compounding effect is severe: declining enrollment, increasing uncompensated care, and reduced reimbursement
- Compounding that pressure is the elimination of prospective payment system rates for individuals with
- Compounding that pressure is the elimination of prospective payment system rates for individuals with
- that consolidates and manages rebate negotiations, invoicing, and collection activities from pharmaceutical
Summary:
The subcommittee heard an extended briefing on the impacts of H.R. 1 on Medi-Cal and CalFresh, followed by testimony from the Legislative Analyst’s Office and county officials. DHCS described major Medi-Cal changes in H.R. 1, including work/community engagement requirements, six-month redeterminations, reduced federal matching for some emergency services, narrower immigrant eligibility, reduced retroactive coverage, and limits on provider taxes and directed payments. CDSS outlined CalFresh changes, especially the expanded able-bodied adults without dependents time limit, reduced exemptions and waivers, and the new federal-state-county administrative cost split. Both departments emphasized implementation plans, automation, outreach, and county coordination, while acknowledging significant expected coverage losses and administrative burden.
The LAO and an independent policy expert discussed how H.R. 1 could increase demand on county indigent care systems and public hospitals as people lose Medi-Cal. They reviewed the history of county indigent care, 1991 realignment, and AB 85, explaining that counties already rely on a patchwork of funding and that current realignment revenues are often used for public health rather than indigent care. They warned that counties may face large increases in uninsured residents, with wide variation in how counties respond, and raised concerns about equity, financing, and whether a more standardized state-county program should be created. Committee members pressed witnesses on county funding, exemptions, homelessness, older adults, undocumented residents, and the effect of administrative burden versus true ineligibility.
County representatives from Los Angeles, Santa Clara, Tulare, and San Bernardino described the expected local impacts and asked for additional state support. They said H.R. 1 would drive major losses in Medi-Cal and CalFresh enrollment, increase uncompensated care, strain eligibility staff, and worsen homelessness and food insecurity. Several counties urged the Legislature to fund eligibility workers, preserve enrollment, and consider a CalFresh match waiver; Santa Clara and San Bernardino also cited local tax measures and staffing reductions already underway. No formal vote or committee action was taken in the portion provided.
NH
New Hampshire 2025 Regular Session
House Commerce and Consumer Affairs (04/23/2025)
Transcript Highlights:
- Okay, is affecting ultimately the insurance company’s costs on pharmaceuticals because the insurance
- But they do hold an exclusive of getting their pharmaceuticals from their wholesaler.
- </c><01:40:17.360><c> from</c><01:40:17.600><c> their</c> their pharmaceuticals from their their pharmaceuticals
- HDA is the trade association representing the nation's pharmaceutical wholesale distributors.
- They do not set a drug's list price, determine formularies, dictate pharmaceutical reimbursement rates
Summary:
The committee first heard Senate Bill 47, sponsored by Senator Regina Birdsell at the request of the Insurance Department. The bill would clarify that a birth mother’s health insurance is the primary policy for a newborn’s care unless the mother has no coverage or no employer-sponsored coverage. Birdsell and Insurance Commissioner DJ Benton Court said the measure simply codifies the department’s long-standing interpretation of existing law. Representative Miles asked whether the coverage would extend to a grandchild if a young woman on her parents’ plan had a baby, and Birdsell said it would. The hearing on SB 47 was then closed.
The committee next heard Senate Bill 121, introduced by Grant Bosi for Senator Kevin Avard. The bill requires insurers to notify the Insurance Department when they stop writing an entire line of business or, in some cases, when they change Medicare Advantage offerings. Benton Court said the bill was prompted by disruption in the Medicare Advantage market, where consumers and the department were confused by carriers exiting, changing plans, or narrowing offerings. He said the department does not regulate Medicare Advantage itself, but does license the carriers, and the notice requirement would help the department advise consumers; he also said noncompliance could affect a carrier’s license and could lead to fines. Members discussed the notice period, and the department and AHIP indicated support for changing it from 120 days to 90 days to align with federal timing. The hearing was closed with plans to work on an amendment in subcommittee.
Finally, the committee heard Senate Bill 247, introduced by Representative Brian Cole, which would prohibit network exclusion for pharmacies that refuse to dispense prescriptions when PBM reimbursement is below acquisition cost. Cole said the bill is meant to stop pharmacies from being forced to sell at a loss. Members questioned whether pharmacies voluntarily enter PBM contracts, whether the bill would raise consumer prices, and whether it would mainly affect independent pharmacies. Cole and others said the issue has changed over time because PBMs now control a much larger share of the market, and that the bill would let pharmacies refuse loss-making fills and direct patients to mail order instead. The discussion also noted that the bill excludes Medicare and Medicaid and that the current proposal does not create a middle-ground option for patients to pay a premium at the counter.
CA
California 2025-2026 Regular Session
Assembly Budget Subcommittee No. 1 on Health Mar 3rd, 2025
Transcript Highlights:
- Supply costs have increased on average by 5% since COVID-19 officially ended, and pharmaceutical costs
- We partnered with Amnial Pharmaceuticals through an open request for information process.
- The pharmaceutical sector, as you know, is well known for being secretive and litigious.
- You mentioned the company was Amnial Pharmaceutical. How exactly were they chosen?
- Most pharmaceutical companies have lawsuits against them. That's probably true.
MN
Transcript Highlights:
- </c> requires drug pharmaceutical requires drug pharmaceutical manufacturers<00:13:53.080><c> to</c><
- </c> And yet today we have pharmaceutical And yet today we have pharmaceutical companies<01:15:04.640
- ><c> the</c><01:15:30.840><c> US</c> US pharmaceutical profits in the US US pharmaceutical profits in
- Thanks. or do we stand with the pharmaceutical or do we stand with the pharmaceutical companies<01:18
- pharmaceuticals pharmaceuticals uh<01:30:19.000><c> and</c><01:30:19.200><c> all</c><01:30:19.320><c
LA
Transcript Highlights:
- I will say Texas has had mandatory pharmaceutical price reporting since 2019.
- And so we've heard from the pharmaceutical industry that they either can't supply this, don't have it
- And so we've heard from the pharmaceutical industry that they either can't supply this, don't have it
- Thank you, Chairman, Phil Christopher Nellie here with the Pharmaceutical Care Management Association
- This is an idea that came from the pharmaceutical manufacturers.
Summary:
The House Insurance Committee met on April 29 with a quorum present and took up several insurance and health care-related bills. SB 192, a dental reimbursement bill, was amended to allow dentists to opt in electronically to credit-card payment methods and to clarify applicability and effective date; it was reported as amended. SB 84 would require prostate cancer screening coverage for men over 40 under current clinical guidelines and prohibit cost-sharing; supporters from the American Cancer Society said Louisiana has a high incidence of prostate cancer and that out-of-pocket costs deter early screening. The committee adopted amendments and reported the bill as amended. SB 275, dealing with reimbursement and network participation for certified registered nurse anesthetists, drew support from nursing and hospital groups and was reported favorably. SB 169, a cleanup bill on biomarker testing, was also amended and reported.
The committee spent substantial time on SB 401, which creates a temporary prescription drug affordability board to review pricing data on selected drugs and report findings to the legislature. Supporters said the board would improve transparency and help lawmakers understand drug pricing trends; opponents raised concerns about confidentiality, market effects, and the lack of a defined policy outcome beyond reporting. Amendments narrowed the scope, added confidentiality protections, and removed opposition cards, and the bill was reported as amended. SB 387, a major PBM reform bill tied to SB 401, would change PBM compensation, rebate handling, formulary practices, audits, and appeals, while excluding ERISA plans after discussion and amendment. Supporters argued it would curb spread pricing and other practices that raise costs, while opponents from the Pelican Institute and PCMA warned it would interfere with private contracts, reduce flexibility, and could raise premiums or disrupt city, school board, and small-group plans. After extensive debate and a roll call, SB 387 was reported with amendments by a 10-4 vote.
The committee also considered SB 241, which requires certain insurance adjusters and public adjusters to include license numbers in written communications. After amendments limiting the requirement to individual licenses and removing one statutory reference, the bill was reported as amended. Throughout the meeting, members and witnesses repeatedly discussed the need for transparency in drug pricing and PBM practices, the role of ERISA and non-ERISA plans, and potential impacts on public employers and consumers.
LA
Transcript Highlights:
- I will say Texas has had mandatory pharmaceutical price reporting since 2019.
- And so we've heard from the pharmaceutical industry that they either can't supply this, don't have it
- And so we've heard from the pharmaceutical industry that they either can't supply this, don't have it
- What you're going to hear from the PBMs is they're the only ones that are there keeping pharmaceutical
- This is an idea that came from the pharmaceutical manufacturers.
LA
Transcript Highlights:
- Phil Christopher Nelly with the Pharmaceutical Care Management Association.
- They negotiate discounts with large pharmaceutical manufacturers.
- They negotiate discounts with large pharmaceutical manufacturers.
- Ultimately, drug prices are set by the pharmaceutical manufacturer.
- Ultimately, drug prices are set by the pharmaceutical manufacturer.
WA
Washington 2025-2026 Regular Session
House Health Care & Wellness Jan 20th, 2026 at 01:30 pm
Health Care & Wellness
Transcript Highlights:
- I'm the state representative for the Pharmaceutical Industry Labor Management Association.
- Lee Nugent, I'm the state representative for the Pharmaceutical Industry Labor Management Association
- Manufacturer restrictions do not benefit patients; they simply increase pharmaceutical profits.
- Manufacturer restrictions do not benefit patients; they simply increase pharmaceutical profits.
- In closing, I urge you not to view a vote against this bill as a vote for pharmaceutical companies.
Keywords:
340B drug pricing, healthcare access, patient rights, discounted medications, manufacturer limitations, health professions, plasma donation, physician substitutes, medical regulation, nursing titles, healthcare, regulation, professional standards, licensure, accreditation, opioid treatment, health services, fee authority, public health, 904
WA
Washington 2025-2026 Regular Session
House Health Care & Wellness Jan 20th, 2026
Transcript Highlights:
- I'm the state representative for the Pharmaceutical Industry Labor Management Association, also known
- Lee Nugent, I'm the state representative for the Pharmaceutical Industry Labor Management Association
- They simply increase pharmaceutical profits.
- Manufacturer restrictions do not benefit patients; they simply increase pharmaceutical profits.
- In closing, I urge you not to view a vote against this bill as a vote for pharmaceutical companies.
Summary:
The committee first heard House Bill 2437, which would put the Department of Health’s authority to accredit opioid treatment programs into statute and allow the department to set a fee to cover the cost of those services. The prime sponsor and DOH said the bill would preserve a service that is especially important to tribal and rural providers and would be self-sustaining rather than supported by the general fund. Members asked about the relationship between DOH and HCA and whether the bill would duplicate existing authority; staff and the department said DOH already performs the accrediting role and the bill mainly formalizes that authority and fee-setting power. Public testimony on the bill was then closed.
The committee then held an extensive work session on the federal 340B drug pricing program and later opened public testimony on House Bill 2145, which would prohibit manufacturers, distributors, and third-party logistics providers from restricting 340B drug acquisition or delivery and from requiring claims or utilization data as a condition of access. Committee staff and NCSL gave background on how 340B works, recent growth in the program, contract pharmacy issues, and state efforts in other jurisdictions. Testimony on HB 2145 was sharply divided: hospitals, community health centers, tribal representatives, contract pharmacies, and labor groups said the bill would protect safety-net providers, rural access, HIV and behavioral health services, and tribal programs from manufacturer restrictions; business groups, pharmaceutical companies, and employer coalitions argued the program has expanded beyond its original intent, lacks transparency, shifts costs to employers and taxpayers, and should be addressed through federal reform instead. No vote was taken in the excerpt.
Finally, the committee heard House Bill 2155, which would bar non-human entities from using nursing titles such as RN, APRN, or LPN or otherwise implying they are licensed nurses. The prime sponsor said the bill is intended to protect patients from being misled by AI systems and to preserve transparency and public safety as health care technology expands. The Washington State Nurses Association testified in support, saying AI can be useful but should not replace nurses or be presented as a licensed professional. A member asked about enforcement and liability, and staff said they would follow up on those details.